237 related articles for article (PubMed ID: 25724577)
1. Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective "Lymphomes Malins B" protocols. A Société Française des Cancers de l'Enfant study.
Jourdain A; Auperin A; Minard-Colin V; Aladjidi N; Zsiros J; Coze C; Gandemer V; Bertrand Y; Leverger G; Bergeron C; Michon J; Patte C;
Haematologica; 2015 Jun; 100(6):810-7. PubMed ID: 25724577
[TBL] [Abstract][Full Text] [Related]
2. Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study.
Rigaud C; Auperin A; Jourdain A; Haouy S; Couec ML; Aladjidi N; Gandemer V; Lambliotte A; Plat G; Landman-Parker J; Michon J; Leblanc T; Patte C; Minard-Colin V
Pediatr Blood Cancer; 2019 Sep; 66(9):e27873. PubMed ID: 31207026
[TBL] [Abstract][Full Text] [Related]
3. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.
Patte C; Auperin A; Michon J; Behrendt H; Leverger G; Frappaz D; Lutz P; Coze C; Perel Y; Raphaël M; Terrier-Lacombe MJ;
Blood; 2001 Jun; 97(11):3370-9. PubMed ID: 11369626
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
Brice P; Bouabdallah R; Moreau P; Divine M; André M; Aoudjane M; Fleury J; Anglaret B; Baruchel A; Sensebe L; Colombat P
Bone Marrow Transplant; 1997 Jul; 20(1):21-6. PubMed ID: 9232251
[TBL] [Abstract][Full Text] [Related]
5. [Clinical pathologic characteristics and treatment outcomes of 19 relapsed pediatric B-cell lymphoma].
Huang S; Jin L; Yang J; Duan YL; Zhang M; Zhou CJ; Ma XL; Zhang YH
Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):748-753. PubMed ID: 29050112
[No Abstract] [Full Text] [Related]
6. Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Société Française de Lutte contre le Cancer des Enfants et des Adolescents (SFCE).
Gorde-Grosjean S; Oberlin O; Leblanc T; Pacquement H; Donadieu J; Lambilliotte A; Schell M; Dommange F; Munzer M; Paillard C; Schmitt C; Lutz P; Edan C; Ansoborlo S; Stephan JL; Michel G; Thomas C; Perel Y; Robert A; Landman-Parker J
Br J Haematol; 2012 Sep; 158(5):649-56. PubMed ID: 22757721
[TBL] [Abstract][Full Text] [Related]
7. Curability of relapsed childhood B-cell non-Hodgkin's lymphoma after intensive first line therapy: a report from the Société Française d'Oncologie Pédiatrique.
Philip T; Hartmann O; Pinkerton R; Zucker JM; Gentet JC; Lamagnere JP; Berhendt H; Perel Y; Otten J; Lutz P
Blood; 1993 Apr; 81(8):2003-6. PubMed ID: 8471762
[TBL] [Abstract][Full Text] [Related]
8. Outcome for patients with leukemia, multiple myeloma and lymphoma who relapse after high dose therapy and autologous stem cell support.
Johnsen HE; Björkstrand B; Carlson K; Gruber A; Blystad A; Fast A; Boesen AM; Björkholm M; Sallerfors B; Ruutu T; Carneskog J; Malm A; Geisler C; Lehtinen M; Schrøder H; Brinch L; Remes K; Tidefelt U; Heilmann C; Hörnsten P; Thorling K; Daugaard G
Leuk Lymphoma; 1996 Dec; 24(1-2):81-91. PubMed ID: 9049964
[TBL] [Abstract][Full Text] [Related]
9. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle.
André M; Henry-Amar M; Pico JL; Brice P; Blaise D; Kuentz M; Coiffier B; Colombat P; Cahn JY; Attal M; Fleury J; Milpied N; Nedellec G; Biron P; Tilly H; Jouet JP; Gisselbrecht C
J Clin Oncol; 1999 Jan; 17(1):222-9. PubMed ID: 10458237
[TBL] [Abstract][Full Text] [Related]
10. Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of second-line chemotherapy.
Winter S; Fasola S; Brisse H; Mosseri V; Orbach D
Pediatr Blood Cancer; 2015 Nov; 62(11):1935-41. PubMed ID: 26150380
[TBL] [Abstract][Full Text] [Related]
11. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
12. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients].
Qin Y; Shi YK; He XH; Han XH; Zhou SY; Liu P; Yang JL; Yang S; Zhang CG; Dong M; Zhou LQ; Wang JW; Feng FY; Sun Y
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):469-73. PubMed ID: 19950562
[TBL] [Abstract][Full Text] [Related]
14. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
15. [Treatment outcomes and prognostic analyses of relapsed or refractory T-cell non-Hodgkin's lymphoma].
Gao Y; Huang HQ; Lin XB; Cai QQ; Pan ZH; Wang BF; Bu Q
Ai Zheng; 2007 Aug; 26(8):909-13. PubMed ID: 17697558
[TBL] [Abstract][Full Text] [Related]
16. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.
Oberlin O; Rey A; Desfachelles AS; Philip T; Plantaz D; Schmitt C; Plouvier E; Lejars O; Rubie H; Terrier P; Michon J;
J Clin Oncol; 2006 Aug; 24(24):3997-4002. PubMed ID: 16921053
[TBL] [Abstract][Full Text] [Related]
17. Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group.
Attarbaschi A; Dworzak M; Steiner M; Urban C; Fink FM; Reiter A; Gadner H; Mann G
Pediatr Blood Cancer; 2005 Jan; 44(1):70-6. PubMed ID: 15368550
[TBL] [Abstract][Full Text] [Related]
18. Successful salvage chemotherapy for isolated central nervous system (CNS) relapse in Burkitt lymphoma: monocentric experience of 3 pediatric patients.
Baleydier F; Pondarre C; Pages MP; Mialou V; Kebaili K; Pracros JP; Bertrand Y
J Pediatr Hematol Oncol; 2008 Dec; 30(12):972-5. PubMed ID: 19131795
[TBL] [Abstract][Full Text] [Related]
19. [Prognosis of hematological patients with relapse following high-dose chemotherapy and autologous stem cell transplantation].
Baggers J; Johnsen HE
Ugeskr Laeger; 1998 Sep; 160(38):5505-8. PubMed ID: 9763925
[TBL] [Abstract][Full Text] [Related]
20. Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Osumi T; Mori T; Fujita N; Saito AM; Nakazawa A; Tsurusawa M; Kobayashi R
Pediatr Blood Cancer; 2016 Oct; 63(10):1794-9. PubMed ID: 27314926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
